STOCK TITAN

Relmada Therapeutics, Inc. (RLMD) Net Income by Year

RLMD

Relmada Therapeutics, Inc. reported $0 in net income in fiscal year 2025. The table below carries 15 fiscal years, from 2010 to 2025, and the quarters Relmada Therapeutics, Inc. has filed alongside them.

FY2025 annual
Net Income $0
Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Currency USD

Annual figures, oldest first. Point at a bar to read its period.

RLMD Net Income by Fiscal Year

Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.

MetricFY25DEF 14AFY24DEF 14AFY23DEF 14AFY2210-KFY2110-KFY2010-KFY1910-KFY1810-KFY1710-KFY1610-KFY1510-KFY1310-KFY1210-KFY1110-KFY1010-K
Net Income$0$0$0+100.0%-$157.0M-24.9%-$125.8M-111.5%-$59.5M-296.2%-$15.0M-67.5%-$9.0M-42.5%-$6.3M-111.3%-$3.0M+85.7%-$20.8MN/AN/A-$874K-5.2%-$831K

RLMD Net Income by Quarter

Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.

MetricQ2'2610-QQ1'2610-QQ4'2510-QQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KQ3'2410-QQ2'2410-QQ1'2410-QQ4'2310-KQ3'2310-Q
Net Income-$12.9M-30.9%-$19.1M-8.5%N/A-$10.1M+53.6%-$9.9M+44.5%-$17.6M+19.6%N/A-$21.7M+1.3%-$17.8M+29.8%-$21.8M+17.1%N/A-$22.0M+44.2%

What net income means

Net income is what is left of revenue once every cost is counted, interest and tax included, so a company can grow its sales and still report a loss on this line.

More Relmada Therapeutics, Inc. financials

Frequently Asked Questions

What was Relmada Therapeutics, Inc.'s net income in fiscal year 2025?

Relmada Therapeutics, Inc. reported $0 in net income in fiscal year 2025.

How has Relmada Therapeutics, Inc.'s net income changed over the years?

Across the 15 fiscal years this page covers, Relmada Therapeutics, Inc. (RLMD) net income went from -$831K in fiscal year 2010 to $0 in fiscal year 2025.

What was Relmada Therapeutics, Inc.'s net income in the most recent quarter?

Relmada Therapeutics, Inc. (RLMD) reported -$12.9M in net income in Q2 2026. This represents a decrease of 30.9% from the same quarter a year earlier.

Net income is what is left of revenue once every cost is counted, interest and tax included, so a company can grow its sales and still report a loss on this line. This page lists what Relmada Therapeutics, Inc. (RLMD) reported on that line in every period on record.